{"__slider":[],"__countdown":[{"gallery":[],"secstyle":"","imageObject":"202311160211001107.jpg","imageSecond":false,"sectionbg":"","background_image":false,"id":214,"title":" Slow And Steady Wins The Race\u003Cbr\u003EWith Regencell Bioscience","subtitle":"","social":{"instagram":"","facebook":"","linkedin":"","youtube":""},"content":"\u003Cdiv class=\"_content\"\u003E\u003Ch6 style=\"text-align:justify\"\u003ESummary\u003C\/h6\u003E\r\n\r\n\u003Cul\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003EMajority shareholders of Regencell are insider investors.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell is comfortably poised amidst turbulent market conditions, especially for a biotech stock.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003EThe company has a list of successful clinical trials, with more to come in the year.\u003C\/li\u003E\r\n\u003C\/ul\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInvestors from all corners of the market are shrieking to shield their portfolios against a looming recession that\u2019s looking to threaten the market as major league stocks have performed poorly over the last couple of months.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWith the Fed\u2019s aggressive\u00a0rate hike policy as an arsenal to dampen soaring inflation, which hit another fresh high of 9.1% in June, investors are seeking some form of continuity and security in the stock market as conditions only become more choppy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIt\u2019s been a tumultuous season so far, and value investors who bought in May and went away are perhaps now jumping to get a hand back on their portfolios.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough conditions aren\u2019t favorable, some sectors have been receiving growing interest from investors in the last few months as inflation, and rising interest rates are hurting companies\u2019 bottom line performance.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESo while experts and investors are split over the shaky economic conditions, where are they looking now to find a safe haven that can prove to deliver on its performance and return on investment?\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EIs Biotech The Solution Many Are Looking For?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EBiotech and bioscience stocks have seen a bumpy start to the year, with companies experiencing major stock sell-offs as tourist investors\u00a0\u003Ca href=\"https:\/\/www.ft.com\/content\/bfd7d96f-2af9-4614-b1eb-78949365de9a\" rel=\"nofollow\"\u003Edumped their stocks\u003C\/a\u003E\u00a0as interest and hype surrounding the pandemic started winding down.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs investors with no interest or knowledge of biotech left the market, it caused a dramatic drop in prices. The biotechnology sector has now become a hunting ground for hedge funds on the lookout for bargain stocks, and some have already scooped up stocks or even launched portfolios to capitalize on the turbulence.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s been a lot of up and down in the biotech market, but some are proving strong and steady against a backdrop of immense economic uncertainty.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EWhat\u2019s Your Slow And Steady?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOne company of interest in this specific category is\u00a0\u003Ca href=\"https:\/\/www.regencellbioscience.com\/\" rel=\"nofollow\"\u003ERegencell Bioscience Holdings Limited\u003C\/a\u003E\u00a0(NASDAQ:\u003Ca href=\"https:\/\/seekingalpha.com\/symbol\/RGC?source=content_type%3Areact%7Csection%3Amain_content%7Cbutton%3Abody_link\" title=\"Regencell Bioscience Holdings Limited\"\u003ERGC\u003C\/a\u003E), an early-stage\u00a0\u003Ca href=\"http:\/\/www.nasdaq.com\/market-activity\/stocks\/rgc\" rel=\"nofollow\"\u003Ebioscience company\u003C\/a\u003E\u00a0focusing on the research, development, and commercialization of Traditional Chinese Medicine (\u201cTCM\u201d).\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERGC has kept investors interested and has received media attention for all the right reasons; the most recent \u2013 the company\u2019s chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to\u00a0\u003Ca href=\"http:\/\/www.businesswire.com\/news\/home\/20220516005619\/en\/Regencell-Bioscience-Holdings-Limited-Announces-Over-5-Million-Ordinary-Share-Purchases-by-CEO\" rel=\"nofollow\"\u003Epurchase\u003C\/a\u003E\u00a0ordinary RGC shares through the open market to support the growth and potential of the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EWhy Does RGC Make Sense, For Now At Least?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERGC is not ordinary, and in many ways, we can see why investors have started noticing the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESo far, year-to-date share prices have increased by 17.03% while the\u00a0\u003Ca href=\"https:\/\/www.marketwatch.com\/investing\/index\/nbi\" rel=\"nofollow\"\u003ENasdaq Biotechnology Index\u003C\/a\u003E\u00a0has only gone up by 2.69%. On average, share prices are zig-zagging between $34.79 and $35.84, and some investors have set up their year range closer to $59.00 per share.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFor the six months between July 2021 and December 2021, the company reported a basic diluted loss per share of $0.29, compared to $0.03 for the same period of 2020.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe loss could be attributed to the company\u2019s sudden increase in operating expenses, which jumped from $368,465 for the 6 months ending December 31, 2020, to $3,658,906 for the same period in 2021, an increase of roughly 893%.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe company\u00a0\u003Ca href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001829667\/000121390022030951\/ea160976ex99-1_regencellbio.htm\" rel=\"nofollow\"\u003Ereported\u003C\/a\u003E\u00a0cash availability of $19 million in December 2021, compared to $0.06 million in June 2021. The main source of cash came from net proceeds of the company\u2019s IPO, including proceeds from the sales of over-allotment shares, totaling approximately 22.7 million.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInitially, when the company went public back in July 2021, share prices were well below their current levels, and a month later, in August 2021, share prices jumped as much as 204% in a single trading session. Since going public, Regencell has treated more than 88 COVID patients with over 94% effectiveness in eliminating symptoms within 6 days; they have ongoing ADHD\/ASD clinical studies and were included in the MSCI world microcap index. RGC was also one of the top best-performing stocks on Nasdaq in 2021, according to www.stockanalysis.com.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ELate last year, Regencell entered preliminary trials for ADHD\/ASD. During this time, the stock was trading in the low $20\u2019s range. By mid-February 2022, share prices had\u00a0\u003Ca href=\"https:\/\/pulse2.com\/regencell-bioscience-holdings-nasdaq-rgc-over-40-pre-market-details\/\" rel=\"nofollow\"\u003Eclimbed over $40\u003C\/a\u003E\u00a0before scaling down to the $20\u2019s range.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough market conditions have been volatile and investor sentiment negative, RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company\u2019s RGC-COV19 TCM formula.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFrom our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe promising track record and positive clinical results have kept investors interested as RGC has remained relatively stable and resolute in its performance. For investors who can digest small purchases a lot better, RGC could outpace sluggish market conditions.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003ERGC Offers Stability\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOne of the leading reasons or factors that have made RGC stable is its unique ownership structure. Currently, individual insiders possess over 81% of the company\u2019s shares, a majority that stands to benefit the most from the stock\u2019s relatively good performance so far.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOn the one hand, RGC is mostly owned by founder and CEO Yat-Gai Au, who is the largest shareholder with an 81% stake. On the other side of the coin, the remaining shareholders own roughly 19% of RGC stock.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIf we had to look at the most recent data, currently, insider owners own at least $333 million of the $416 million business. When studying these circumstances can act as an indication to investors that the majority of owners are executives, managers, and leaders all within the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EBoth general public ownership (11.2%) and private equity ownership (7.6%) are still substantial, and it gives them some power to influence company decisions on performance and growth. Yet, while large enough to play a role, it\u2019s not big enough to change company policy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs most of the power is vested and held within the company, it gives them better control over the decision-making and their path towards growth. So for investors who are looking to make a jump at RGC, there\u2019s a bit more stability and certainty in its current practice, seeing as board members are investing alongside casual investors.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s a tug and pull to this sort of tactic, which can make some investors a bit more wary of the general conditions of the company and its growth potential. Yet, with most of its influence coming from within, performance indicators can be measured based on members\u2019 strategic management and goals.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EMinimal Impact Derived From The Pandemic\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWhile the pandemic has affected a majority of global businesses and trade, Regencell was no different, having to increase spending on clinical research that was for some time paused due to local lockdown protocols.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe pandemic has also affected the company\u2019s ability to initiate and complete certain studies and has increased the backlog of regulatory activities. The company saw a significant decrease in available funding opportunities for its clinical studies and research, which only caused increased delays in trial development and results.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere is, however, one positive side to the increased delays. According to the company, they have yet to see any material business disruptions or impairments of any assets as a result of the pandemic. Furthermore, the company has focused efforts on more measurable factors to help them determine its pace of growth as the pandemic evolves.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough the decision may have placed them behind their competitors, to some extent, it\u2019s still allowed them to readjust as they find themselves in a post-pandemic economy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EThe Bottom Line\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s a lot of volatility involved when it comes to the performance of biotech and bioscience stocks at the moment, but the rest of the market is also prone to some downturn in the coming months.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWhile Regencell still needs to build up its portfolio and general investor trust, there\u2019s already a clear indication that the CEO is willing to put money where his mouth is.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ELooking to vest more power within the company and less so with shareholders gives an idea that the company is focused and driven to meet its strategic goals. So far, Regencell has a positive clinical trial track record, with board members and executives remaining steadfast in their ability to influence the bioscience market through TCM.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell is in a comfortable position right now and perhaps a good choice for investors looking to have something more stable among the turbulent market conditions. Decently priced, and poised for growth, perhaps RGC is just what seasoned investors need to spruce up their summer portfolios.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESource from:\u00a0\u003Ca href=\"https:\/\/seekingalpha.com\/article\/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience\"\u003EThe Seeking Alpha (The article was written by Value Walk)\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E","blurb":"","link":"","linktitle":"","links":[],"alink":"","buttons":"","imageObjectTitle":"","imageObjectSrc":"management.file\/img\/202311160211001107.jpg","imageObjectImg":"\u003Cdiv class=\"_imgobj p-r\"\u003E\u003Cimg src=\"management.file\/img\/202311160211001107.jpg\" \/\u003E\u003C\/div\u003E","imageObjectBg":"background-image: url(management.file\/img\/202311160211001107.jpg);","imageSecondTitle":"","imageSecondSrc":"","imageSecondImg":"","imageSecondBg":"","ittlsec":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003E Slow And Steady Wins The Race\u003Cbr\u003EWith Regencell Bioscience\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","h":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003E Slow And Steady Wins The Race\u003Cbr\u003EWith Regencell Bioscience\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","maintitle":"","sectitle":"\u003Cdiv class=\"_secttlbx\"\u003E\n \n \u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\n \n \u003Cdiv class=\"_ttlcontent _content\"\u003E\u003Ch6 style=\"text-align:justify\"\u003ESummary\u003C\/h6\u003E\r\n\r\n\u003Cul\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003EMajority shareholders of Regencell are insider investors.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003ERegencell is comfortably poised amidst turbulent market conditions, especially for a biotech stock.\u003C\/li\u003E\r\n\t\u003Cli style=\"text-align: justify;\"\u003EThe company has a list of successful clinical trials, with more to come in the year.\u003C\/li\u003E\r\n\u003C\/ul\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInvestors from all corners of the market are shrieking to shield their portfolios against a looming recession that\u2019s looking to threaten the market as major league stocks have performed poorly over the last couple of months.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWith the Fed\u2019s aggressive\u00a0rate hike policy as an arsenal to dampen soaring inflation, which hit another fresh high of 9.1% in June, investors are seeking some form of continuity and security in the stock market as conditions only become more choppy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIt\u2019s been a tumultuous season so far, and value investors who bought in May and went away are perhaps now jumping to get a hand back on their portfolios.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough conditions aren\u2019t favorable, some sectors have been receiving growing interest from investors in the last few months as inflation, and rising interest rates are hurting companies\u2019 bottom line performance.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESo while experts and investors are split over the shaky economic conditions, where are they looking now to find a safe haven that can prove to deliver on its performance and return on investment?\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EIs Biotech The Solution Many Are Looking For?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EBiotech and bioscience stocks have seen a bumpy start to the year, with companies experiencing major stock sell-offs as tourist investors\u00a0\u003Ca href=\"https:\/\/www.ft.com\/content\/bfd7d96f-2af9-4614-b1eb-78949365de9a\" rel=\"nofollow\"\u003Edumped their stocks\u003C\/a\u003E\u00a0as interest and hype surrounding the pandemic started winding down.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs investors with no interest or knowledge of biotech left the market, it caused a dramatic drop in prices. The biotechnology sector has now become a hunting ground for hedge funds on the lookout for bargain stocks, and some have already scooped up stocks or even launched portfolios to capitalize on the turbulence.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s been a lot of up and down in the biotech market, but some are proving strong and steady against a backdrop of immense economic uncertainty.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EWhat\u2019s Your Slow And Steady?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOne company of interest in this specific category is\u00a0\u003Ca href=\"https:\/\/www.regencellbioscience.com\/\" rel=\"nofollow\"\u003ERegencell Bioscience Holdings Limited\u003C\/a\u003E\u00a0(NASDAQ:\u003Ca href=\"https:\/\/seekingalpha.com\/symbol\/RGC?source=content_type%3Areact%7Csection%3Amain_content%7Cbutton%3Abody_link\" title=\"Regencell Bioscience Holdings Limited\"\u003ERGC\u003C\/a\u003E), an early-stage\u00a0\u003Ca href=\"http:\/\/www.nasdaq.com\/market-activity\/stocks\/rgc\" rel=\"nofollow\"\u003Ebioscience company\u003C\/a\u003E\u00a0focusing on the research, development, and commercialization of Traditional Chinese Medicine (\u201cTCM\u201d).\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERGC has kept investors interested and has received media attention for all the right reasons; the most recent \u2013 the company\u2019s chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to\u00a0\u003Ca href=\"http:\/\/www.businesswire.com\/news\/home\/20220516005619\/en\/Regencell-Bioscience-Holdings-Limited-Announces-Over-5-Million-Ordinary-Share-Purchases-by-CEO\" rel=\"nofollow\"\u003Epurchase\u003C\/a\u003E\u00a0ordinary RGC shares through the open market to support the growth and potential of the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EWhy Does RGC Make Sense, For Now At Least?\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERGC is not ordinary, and in many ways, we can see why investors have started noticing the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESo far, year-to-date share prices have increased by 17.03% while the\u00a0\u003Ca href=\"https:\/\/www.marketwatch.com\/investing\/index\/nbi\" rel=\"nofollow\"\u003ENasdaq Biotechnology Index\u003C\/a\u003E\u00a0has only gone up by 2.69%. On average, share prices are zig-zagging between $34.79 and $35.84, and some investors have set up their year range closer to $59.00 per share.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFor the six months between July 2021 and December 2021, the company reported a basic diluted loss per share of $0.29, compared to $0.03 for the same period of 2020.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe loss could be attributed to the company\u2019s sudden increase in operating expenses, which jumped from $368,465 for the 6 months ending December 31, 2020, to $3,658,906 for the same period in 2021, an increase of roughly 893%.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe company\u00a0\u003Ca href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/0001829667\/000121390022030951\/ea160976ex99-1_regencellbio.htm\" rel=\"nofollow\"\u003Ereported\u003C\/a\u003E\u00a0cash availability of $19 million in December 2021, compared to $0.06 million in June 2021. The main source of cash came from net proceeds of the company\u2019s IPO, including proceeds from the sales of over-allotment shares, totaling approximately 22.7 million.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EInitially, when the company went public back in July 2021, share prices were well below their current levels, and a month later, in August 2021, share prices jumped as much as 204% in a single trading session. Since going public, Regencell has treated more than 88 COVID patients with over 94% effectiveness in eliminating symptoms within 6 days; they have ongoing ADHD\/ASD clinical studies and were included in the MSCI world microcap index. RGC was also one of the top best-performing stocks on Nasdaq in 2021, according to www.stockanalysis.com.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ELate last year, Regencell entered preliminary trials for ADHD\/ASD. During this time, the stock was trading in the low $20\u2019s range. By mid-February 2022, share prices had\u00a0\u003Ca href=\"https:\/\/pulse2.com\/regencell-bioscience-holdings-nasdaq-rgc-over-40-pre-market-details\/\" rel=\"nofollow\"\u003Eclimbed over $40\u003C\/a\u003E\u00a0before scaling down to the $20\u2019s range.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough market conditions have been volatile and investor sentiment negative, RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company\u2019s RGC-COV19 TCM formula.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFrom our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe promising track record and positive clinical results have kept investors interested as RGC has remained relatively stable and resolute in its performance. For investors who can digest small purchases a lot better, RGC could outpace sluggish market conditions.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003ERGC Offers Stability\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOne of the leading reasons or factors that have made RGC stable is its unique ownership structure. Currently, individual insiders possess over 81% of the company\u2019s shares, a majority that stands to benefit the most from the stock\u2019s relatively good performance so far.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOn the one hand, RGC is mostly owned by founder and CEO Yat-Gai Au, who is the largest shareholder with an 81% stake. On the other side of the coin, the remaining shareholders own roughly 19% of RGC stock.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIf we had to look at the most recent data, currently, insider owners own at least $333 million of the $416 million business. When studying these circumstances can act as an indication to investors that the majority of owners are executives, managers, and leaders all within the company.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EBoth general public ownership (11.2%) and private equity ownership (7.6%) are still substantial, and it gives them some power to influence company decisions on performance and growth. Yet, while large enough to play a role, it\u2019s not big enough to change company policy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAs most of the power is vested and held within the company, it gives them better control over the decision-making and their path towards growth. So for investors who are looking to make a jump at RGC, there\u2019s a bit more stability and certainty in its current practice, seeing as board members are investing alongside casual investors.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s a tug and pull to this sort of tactic, which can make some investors a bit more wary of the general conditions of the company and its growth potential. Yet, with most of its influence coming from within, performance indicators can be measured based on members\u2019 strategic management and goals.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EMinimal Impact Derived From The Pandemic\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWhile the pandemic has affected a majority of global businesses and trade, Regencell was no different, having to increase spending on clinical research that was for some time paused due to local lockdown protocols.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThe pandemic has also affected the company\u2019s ability to initiate and complete certain studies and has increased the backlog of regulatory activities. The company saw a significant decrease in available funding opportunities for its clinical studies and research, which only caused increased delays in trial development and results.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere is, however, one positive side to the increased delays. According to the company, they have yet to see any material business disruptions or impairments of any assets as a result of the pandemic. Furthermore, the company has focused efforts on more measurable factors to help them determine its pace of growth as the pandemic evolves.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAlthough the decision may have placed them behind their competitors, to some extent, it\u2019s still allowed them to readjust as they find themselves in a post-pandemic economy.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u00a0\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003EThe Bottom Line\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EThere\u2019s a lot of volatility involved when it comes to the performance of biotech and bioscience stocks at the moment, but the rest of the market is also prone to some downturn in the coming months.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EWhile Regencell still needs to build up its portfolio and general investor trust, there\u2019s already a clear indication that the CEO is willing to put money where his mouth is.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ELooking to vest more power within the company and less so with shareholders gives an idea that the company is focused and driven to meet its strategic goals. So far, Regencell has a positive clinical trial track record, with board members and executives remaining steadfast in their ability to influence the bioscience market through TCM.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ERegencell is in a comfortable position right now and perhaps a good choice for investors looking to have something more stable among the turbulent market conditions. Decently priced, and poised for growth, perhaps RGC is just what seasoned investors need to spruce up their summer portfolios.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESource from:\u00a0\u003Ca href=\"https:\/\/seekingalpha.com\/article\/4534812-slow-and-steady-wins-the-race-with-regencell-bioscience\"\u003EThe Seeking Alpha (The article was written by Value Walk)\u003C\/a\u003E\u003C\/p\u003E\r\n\u003C\/div\u003E\n \u003C\/div\u003E","iframe":"","date":"","documentSrc":"","document":"","documentTitle":"","videoSrc":"","video":"","videoTitle":""}],"__step":[],"__otherstep":[],"__textslide":[],"__message1":[],"__message2":[],"__gallery":[]}
